These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1389 related items for PubMed ID: 16163194

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 3. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec 01; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM.
    Future Oncol; 2006 Oct 01; 2(5):591-602. PubMed ID: 17026451
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C, Herrstedt J.
    Expert Rev Anticancer Ther; 2010 Feb 01; 10(2):137-48. PubMed ID: 20131990
    [Abstract] [Full Text] [Related]

  • 9. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G.
    Crit Rev Oncol Hematol; 2009 Apr 01; 70(1):83-91. PubMed ID: 18723369
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V.
    J Support Oncol; 2006 Sep 01; 4(8):403-8. PubMed ID: 17004515
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES.
    Am J Ther; 2010 Sep 01; 17(5):476-86. PubMed ID: 20844345
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J.
    Eur J Cancer Care (Engl); 2013 Jan 01; 22(1):41-50. PubMed ID: 22519361
    [Abstract] [Full Text] [Related]

  • 19. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, Pinto A.
    Crit Rev Oncol Hematol; 2012 Jul 01; 83(1):59-70. PubMed ID: 22321726
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.